ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0750

Quality Improvement Project to Increase the Rate of Vaccination with Pneumococcal Vaccines (PCV13 prime-PPSV23 Boost Strategy) Among Adult Patients with Autoimmune Inflammatory Rheumatic Diseases (AIIRD) Within Nationwide Health Organization

Victoria Furer, Hagit Sarbagil-Maman and Ori Elkayam, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Meeting: ACR Convergence 2022

Keywords: Administrative Data, autoimmune diseases, Infection, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Health Services Research Poster II

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Patients with autoimmune inflammatory rheumatic diseases (AIIRD) are susceptible for pneumococcal disease. Two vaccines against S. pneumoniae are currently recommended for use: a 23-valent polysaccharide vaccine (PPSV23) and a 13-valent pneumococcal CRM197 conjugate vaccine (PCV13). Stepwise pneumococcal vaccination, a PCV13 prime-PPSV23 boost strategy with an interval of at least 8 weeks between the two vaccinations, is now recommended by the Center for Disease Control and Prevention (CDC). Yet, real-life evidence shows a suboptimal uptake of pneumococcal vaccination among AIIRD patients.

The primary purpose of the project was to increase pneumococcal vaccine uptake, implementing the PCV13 prime-PPSV23 boost strategy among the adult AIIRD population within an Israeli nationwide health organization. The secondary aim was to investigate potential causes for non-adherence with the vaccination plan.

Methods: Quality improvement (QI) intervention program conducted within Maccabi Health Services (MHS) during 2019-2020 included electronic reminders linked order sets and outreach to patients with adult AIIRD identified by ICD-9-CM and MHS codes along with educational activities. We investigated the pneumococcal vaccination rate following the QI program and identified the factors associated with vaccination using univariate and multivariate logistic regressions. Multivariate models were adjusted for gender, age, COPD, CHF, prior influenza vaccination, and prior PPSV23 vaccination.

Results: A total of 9,247 AIIRD patients (62.6% females, age (mean±SD) 58.5±16.7 years) were defined as candidates for pneumococcal vaccination. Rheumatoid arthritis, psoriatic arthritis (PsA), ankylosing spondylitis, and systemic vasculitis were the commonest diseases, 39.9% (n=3,694), 26.4% (n=2,441), 13.6% (n=1,260), and 8.7% (n=804), respectively (Table 1).

The QI program issued 12.5±10.8/patient electronic reminders within the electronic medical records for pneumococcal vaccination. Following the intervention, PCV13-PPSV23 and PCV13 vaccination rates were 19.6% (n=1,811) and 34.5% (n=3,190), respectively (Table 2). Patients with inflammatory myopathies (iIM) and PsA had the highest rates of the prime-boost vaccination, 28.4% (n=31) and 22.6% (n=552), respectively. A total of 43.7% (n=4,045) of patients did not respond to the study intervention.

Adjusted predictors for the adherence with vaccination included overweight – OR 2.3, 95% CI 1.397-2.548, high socioeconomic status – OR 1.56, 95% CI 1.377-1.738, IIM – OR 1.768, 95% CI 1.155-2.707, biologic DMARDs – OR 1.590 95% CI 1.449-1.746, csDMARDs – OR 1.35 95% CI 1.220-1.492, immunosuppressants – OR 1.2 95% CI 1.072-1.350, tsDMARDs – OR 1.48 95% CI 1.28-1.71, and CS – OR 1.145 95% CI 1.036-1.264 (Table 3). Utilization of medical services, including primary care visits and rheumatology clinic visits, was higher in vaccinated compared to non-vaccinated AIIRD patients.

Conclusion: QI intervention program targeting the AIIRD population within a nationwide healthcare organization moderately increased the rate of pneumococcal vaccination. There remains a significant scope to improve pneumococcal vaccination uptake among patients with AIIRD.

Supporting image 1

Table 1. Study cohort characteristics.

Supporting image 2

Table 2. Vaccination data.

Supporting image 3

Table 3. Predictors for PCV13 vaccination (as a single vaccine or prime-boost strategy) – univariate and multivariate analyses.
Multivariate models are adjusted to age, gender, COPD, CHF, Influenza vaccination, and prior PPSV23 vaccination


Disclosures: V. Furer, None; H. Sarbagil-Maman, None; O. Elkayam, Pfizer, Eli Lilly, AbbVie/Abbott, Novartis, Janssen, Boehringer-Ingelheim.

To cite this abstract in AMA style:

Furer V, Sarbagil-Maman H, Elkayam O. Quality Improvement Project to Increase the Rate of Vaccination with Pneumococcal Vaccines (PCV13 prime-PPSV23 Boost Strategy) Among Adult Patients with Autoimmune Inflammatory Rheumatic Diseases (AIIRD) Within Nationwide Health Organization [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/quality-improvement-project-to-increase-the-rate-of-vaccination-with-pneumococcal-vaccines-pcv13-prime-ppsv23-boost-strategy-among-adult-patients-with-autoimmune-inflammatory-rheumatic-diseases-aii/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/quality-improvement-project-to-increase-the-rate-of-vaccination-with-pneumococcal-vaccines-pcv13-prime-ppsv23-boost-strategy-among-adult-patients-with-autoimmune-inflammatory-rheumatic-diseases-aii/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology